Growth Potential and Future Prospects of Radiopharmaceuticals

Driven by growing global interest in radiopharmaceuticals and theranostics, an increasing number of major pharmaceutical companies are entering the field of nuclear medicine.

According to Nuclear Medicine - Volume I (2025 Edition) published by MEDraysintell, the introduction of new radionuclides and radiopharmaceuticals has accelerated research and development activities across the industry. The report also notes that approximately USD 31.7 billion was invested in mergers and acquisitions within the radiopharmaceutical sector between 2014 and August 2025. As a result, the global nuclear medicine market is expected to maintain a compound annual growth rate (CAGR) of approximately 14% from 2024 to 2034, reaching a market size of more than USD 41-42 billion by 2034.

Amid this rapidly expanding and highly promising industry, we are guided by the following vision: "To enrich every life through innovative diagnosis and treatment enabled by radiopharmaceuticals." In pursuit of this vision, we are advancing the following initiatives to promote the adoption of radiopharmaceuticals and contribute to the continued growth of the nuclear medicine market:

• New Drug Development（＞Pipeline）
• Reliable Supply of Radiopharmaceuticals（＞Chiba Kazusa Akademia Park Factory (tentative name)）
• Comprehensive Solutions Supporting the Adoption of Radiopharmaceuticals（＞Total Solutions）
• Initiatives to Optimize the Regulatory Environment for Radiopharmaceuticals（＞Japan Radiopharmaceuticals Association Website）*External website